These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 8158774)

  • 41. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. The Leuprolide Study Group.
    Sharifi R; Soloway M
    J Urol; 1990 Jan; 143(1):68-71. PubMed ID: 2104638
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
    Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
    Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Continuously proliferative stem germ cells partially repopulate the aged, atrophic rat testis after gonadotropin-releasing hormone agonist therapy.
    Schoenfeld HA; Hall SJ; Boekelheide K
    Biol Reprod; 2001 Apr; 64(4):1273-82. PubMed ID: 11259276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.
    Schulman C; Alcaraz A; Berges R; Montorsi F; Teillac P; Tombal B
    BJU Int; 2007 Jul; 100 Suppl 1():1-5. PubMed ID: 17593201
    [No Abstract]   [Full Text] [Related]  

  • 45. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
    Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
    J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of prostate cancer with gonadotropin-releasing hormone agonists.
    Labrie F; Dupont A; Bélanger A; St-Arnaud R; Giguère M; Lacourcière Y; Emond J; Monfette G
    Endocr Rev; 1986 Feb; 7(1):67-74. PubMed ID: 3514203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation.
    Smith DM; Murphy WM
    Cancer; 1994 Mar; 73(5):1472-7. PubMed ID: 8111715
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence for testicular impairment after long-term treatment with a luteinizing hormone-releasing hormone agonist in elderly men.
    Decensi AU; Guarneri D; Marroni P; Di Cristina L; Paganuzzi M; Boccardo F
    J Urol; 1989 Nov; 142(5):1235-8. PubMed ID: 2530360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacologic profiles of investigational kisspeptin/metastin analogues, TAK-448 and TAK-683, in adult male rats in comparison to the GnRH analogue leuprolide.
    Matsui H; Masaki T; Akinaga Y; Kiba A; Takatsu Y; Nakata D; Tanaka A; Ban J; Matsumoto S; Kumano S; Suzuki A; Ikeda Y; Yamaguchi M; Watanabe T; Ohtaki T; Kusaka M
    Eur J Pharmacol; 2014 Jul; 735():77-85. PubMed ID: 24747751
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia.
    Eri LM; Tveter KJ
    J Urol; 1994 Aug; 152(2 Pt 1):448-52. PubMed ID: 7516978
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term suppression of luteinizing hormone, follicle-stimulating hormone and testosterone by daily administration of leuprolide.
    Glode LM; Smith JA
    J Urol; 1987 Jan; 137(1):57-60. PubMed ID: 3098990
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term effectiveness of luteinizing hormone-releasing hormone agonist or antiandrogen monotherapy in elderly men with localized prostate cancer (T1-2): a retrospective study.
    Raina R; Pahalajani G; Agarwal A; Zippe C
    Asian J Androl; 2007 Mar; 9(2):253-8. PubMed ID: 17334592
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
    Ouzaid I; Rouprêt M
    Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growth inhibition of human prostate tumor cells by an agonist of gonadotrophin-releasing hormone.
    Loop SM; Gorder CA; Lewis SM; Saiers JH; Drivdahl RH; Ostenson RC
    Prostate; 1995 Apr; 26(4):179-88. PubMed ID: 7716082
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.
    Braslis KG; Davi RC; Nelson E; Civantos F; Soloway MS
    Urology; 1995 Feb; 45(2):329-31. PubMed ID: 7855985
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
    Khan MS; O'Brien A
    Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.